55 research outputs found
THE PREVENTION, DIAGNOSIS, AND TREATMENT OF VITAMIN D AND CALCIUM DEFICIENCIES IN THE ADULT POPULATION OF RUSSIA AND IN PATIENTS WITH OSTEOPOROSIS (ACCORDING TO THE MATERIALS OF PREPARED CLINICAL RECOMMENDATIONS)
The paper presents data on the role of vitamin D and calcium in the function of many human organs and tissues.Β Lifestyle, dietary preferences, and insufficient physical activity contribute to the high prevalence of vitamin D and calciumΒ deficiencies in the adult population of Russia, causing different diseases and abnormalities. The authors haveΒ worked out recommendations for the preventive use of vitamin D and calcium in healthy population, give consumptionΒ rates for these substances, and describe the clinical and laboratory signs of vitamin D deficiency and indicationsΒ for screening. They also propose treatment regimens for vitamin D deficiency and depict the signs of intoxication inoverdose. Particular emphasis is laid on the place of vitamin D and calcium in the therapy of osteoporosis
VLIYaNIE TsINAKALTsETA (MIMPARY) NA POChEChNUYu OSTEODISTROFIYu U PATsIENTOV, NAKhODYaShchIKhSYa NA PROGRAMMNOM GEMODIALIZE
Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ ΠΎΠ±Π·ΠΎΡ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π½Π°ΡΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΎΠ±ΠΎΠ±ΡΠ°ΡΡΠΈΠ΅ ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ°Π»ΡΠ½ΡΠ΅ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠΈ ΡΠΈΠ½Π°ΠΊΠ°Π»ΡΠ΅ΡΠ° Π½Π° Π³ΠΎΡΠΌΠΎΠ½Π°Π»ΡΠ½ΠΎ-Π±ΠΈΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΡΠΎΡΡΠΎΡΠ½ΠΎ-ΠΊΠ°Π»ΡΡΠΈΠ΅Π²ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π°, Π½Π° ΠΌΠ°ΡΠΊΠ΅ΡΡ ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΠ·ΠΌΠ°, ΠΌΠΈΠ½Π΅ΡΠ°Π»ΡΠ½ΡΡ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΡ ΠΊΠΎΡΡΠ΅ΠΉ, ΡΠ°ΠΊΠΆΠ΅ Π½Π° Π³ΠΈΡΡΠΎΠΌΠΎΡΡΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΠΈ ΠΏΠΎΡΠ΅ΡΠ½ΠΎΠΉ ΠΎΡΡΠ΅ΠΎΠ΄ΠΈΡΡΡΠΎΡΠΈΠΈ Ρ Π³Π΅ΠΌΠΎΠ΄ΠΈΠ°Π»ΠΈΠ·Π½ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π²ΡΠΎΡΠΈΡΠ½ΡΠΌ Π³ΠΈΠΏΠ΅ΡΠΏΠ°ΡΠ°ΡΠΈΡΠ΅ΠΎΠ·ΠΎ
MEDICAL METHODS OF CORRECTION OF RENAL OSTEODYSTROPHY
The article presents a literature review summarizing the contemporary data on the effects of drug therapy on various parameters of renal osteodystrophy: phosphate binders, vitamin D preparations, bisphosphonates, denosumab, and calcimimetics. We discuss the results of pilot study of the efficacy of teriparatide and denosumab on parameters of bone metabolism in patients with chronic kidney disease
DIAGNOSIS AND TREATMENT OF PATIENTS WITH SECONDARY HYPERPARATHYROIDISM AND RENAL INSUFFICIENCY. THERAPEUTIC POTENTIAL OF PARICALCITOL
A review of the literature is devoted to the issue of secondary hyperparathyroidism (SHPT) with underlying chronic renal failure. Initial manifestations of the disease can be observed even with a minimal decrease in the rate of glomerular filtration and are pathophysiologically associated with violations of normal metabolism of vitamin D with its conversion into D-hormone. SHPT pathogenesis is based on the D-hormone deprivation and triggering of pathophysiology mechanisms of bone remodelling, increased FRP-23, PTH, changes in the serum levels of calcium and phosphorus, which may further lead to significant changes in the bone tissue structure and cardiovascular complications. Active metabolites of vitamin D and vitamin D analogues (Paricalcitol) were developed for the replacement of active forms of vitamin D in conditions of D-hormone deficiency. Due to its chemical structure and pharmacokinetics, Paricalcitol is able to block the synthesis of parathyroid hormone to a greater extent and increase the absorption of calcium and phosphorus in the intestine to a lesser extent, which gives it advantages over pre-existing active metabolite
ANABOLIChESKAYa TERAPIYa OSTEOPOROZA.TERIPAPARATID: EFFEKTIVNOST', BEZOPASNOST' I OBLAST' PRIMENENIYa
This review of the literature has been dedicated to experimental and clinical studies of mechanism of action and efficacy of 1β34 amino acid fragment of parathyroid hormone β teriparatide as well as others contries experience of its prescribtion. Teriparatide is an osteoanabolic agent which stimulates bone formation by affecting bone modeling and by stimulating bone remodeling. The effects on modeling lead to increased bone formation whereas the effects on bone remodeling lead to increased bone turnover. Thus, in its mode of action teriparatide differs from all others medicines currently available to treat osteoporosis. Daily subcutaneous injections of teriparatide are proved to be effective to prevent low-traumatic vertebral and non-vertebral fractures in postmenopausal women with the history of vertebral fractures. Teriparatide is effective to treat osteoporosis in male and even more effective than alendronate to treat glucocorticoid-induced osteoporosis. Due to high cost and some restriction related to the duration of therapy (up to 18 months in Russia and 24 months in others countries) teriparatide should be recommended to treat severe osteoporosis in patients with a history >1 moderate clinical vertebral fracture or two or more vertebral fragility fractures or in case the previous treatment was not effective. Teriparatide should be prescribed after bisphosphonates or other antiosteoporotic treatment, but not in the combination with bisphosphonates. The prescribtion of bisphosphonates after teriparatide is effective to maintaine and further improve the effect. Thus, teriparatide is effective to treat severe osteoporosis and osteoporosis resistant to other therapy
MODERN VIEW ON THE EFFECTIVENESS OF THERAPY FOR POSTMENOPAUSAL OSTEOPOROSIS. INNOVATIVE DRUGS OF TARGETED ACTION
ΠΠΎΡΡΠ΅ΠΏΠ΅Π½Π½ΠΎΠ΅ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΆΠΈΠ·Π½ΠΈ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°, ΡΡΡΠ΅ΠΌΠ»Π΅Π½ΠΈΠ΅ ΠΊ ΡΠ»ΡΡΡΠ΅Π½ΠΈΡ Π΅Π΅ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΡΡΠ΅Π±ΡΠ΅Ρ ΡΠ»ΡΡΡΠ΅Π½ΠΈΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Π°. ΠΡΠ½ΠΎΠ²Π½ΡΡ ΡΠ°ΡΡΡ Π»ΠΈΡ, ΠΏΠΎΠ΄Π²Π΅ΡΠΆΠ΅Π½Π½ΡΡ
ΠΠ, ΡΠΎΡΡΠ°Π²Π»ΡΡΡ ΠΆΠ΅Π½ΡΠΈΠ½Ρ Π² ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π΅. Π Π°Π·Π½ΠΎΡΡΠΎΡΠΎΠ½Π½ΠΈΠΉ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ ΠΊ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ΅ Π²ΠΎΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΈΡ Π±Π°Π»Π°Π½ΡΠ° ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠ°Π±ΠΎΠ»ΠΈΠ·ΠΌΠ° ΠΏΡΠΈΠ²Π΅Π» ΠΊ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΡ Π² ΠΏΡΠ°ΠΊΡΠΈΠΊΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Ρ ΡΠ°Π·Π»ΠΈΡΠ½ΡΠΌΠΈ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠ°ΠΌΠΈ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ. Π ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅Π΅ Π²ΡΠ΅ΠΌΡ ΠΊΡΠ°ΠΉΠ½Π΅ Π²Π°ΠΆΠ½ΡΠΌ Π°ΡΠΏΠ΅ΠΊΡΠΎΠΌ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΈΠ²Π΅ΡΠΆΠ΅Π½Π½ΠΎΡΡΠΈ ΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠΎΠ»ΡΡΠ°ΡΡΠΈΡ
ΠΌΠ½ΠΎΠ³ΠΎΠ»Π΅ΡΠ½Π΅Π΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Π°. ΠΠ½Π½ΠΎΠ²Π°ΡΠΈΠΎΠ½Π½ΡΠΌ ΡΠ°Π³ΠΎΠΌ ΡΠ²Π»ΡΠ΅ΡΡΡ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΠ΅ Π² ΠΏΡΠ°ΠΊΡΠΈΠΊΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π½ΠΎΠ²ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅Π»ΠΎΠ²Π΅ΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ Π»ΠΈΠ³Π°Π½Π΄Ρ RANK Π΄Π΅Π½ΠΎΡΡΠΌΠ°Π±. Π ΠΎΠ±Π·ΠΎΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΌΠ½ΠΎΠ³ΠΎΡΠ΅Π½ΡΡΠΎΠ²ΡΡ
ΡΠ»Π΅ΠΏΡΡ
ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π΄Π΅Π½ΠΎΡΡΠΌΠ°Π±Π° ΠΈ ΠΏΠ΅ΡΠΎΡΠ°Π»ΡΠ½ΡΡ
Π±ΠΈΡΡΠΎΡΡΠΎΠ½Π°ΡΠΎΠ². ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠ΅ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π΄Π΅Π½ΠΎΡΡΠΌΠ°Π±Π° (ΠΏΠΎΠ΄ΠΊΠΎΠΆΠ½ΠΎ 60 ΠΌΠ³ 1 ΡΠ°Π· Π² 6 ΠΌΠ΅Ρ.) Π½Π° ΠΏΡΠΈΡΠΎΡΡ ΠΠΠ Π²ΠΎ Π²ΡΠ΅Ρ
ΠΎΡΠ΄Π΅Π»Π°Ρ
ΡΠΊΠ΅Π»Π΅ΡΠ° (ΠΊΠ°ΠΊ Π±ΠΎΠ³Π°ΡΡΡ
ΡΡΠ°Π±Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΉ, ΡΠ°ΠΊ ΠΈ ΠΊΠΎΡΡΠΈΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΠΊΠΎΡΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΡΡ), Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠΊΠ° ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌΠΎΠ² ΠΏΡΠΈ Ρ
ΠΎΡΠΎΡΠ΅ΠΉ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ
Patologiya kostnoy sistemy pri vtorichnomgiperparatireoze u patsientov s terminal'noystadiey khronicheskoy bolezni pochek na zamestitel'noypochechnoy terapii (gemodializ) (obzor literatury)
- β¦